The 2nd PhI­II schiz­o­phre­nia study for In­tra-Cel­lu­lar drug is a dis­as­ter, shares shred­ded

A year af­ter turn­ing up some mixed schiz­o­phre­nia da­ta from their first late-stage study of their lead drug for schiz­o­phre­nia, In­tra-Cel­lu­lar Ther­a­peu­tics to­day said that the sec­ond late-stage tri­al was a near com­plete flop.

As in many sim­i­lar stud­ies, In­tra-Cel­lu­lar $IT­CI says their psy­chi­atric drug was done in by a high place­bo re­sponse. And like many oth­ers, it is vow­ing to re­main com­mit­ted to the de­vel­op­ment pro­gram.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER